地特胰岛素治疗糖尿病患者严重低血糖。
Dasiglucagon for treating severe hypoglycemia in patients with diabetes.
机构信息
Department of Pharmaceutical, Central Hospital of Linyi City, Yishui, Shandong, China.
Department Ophthalmology, Central Hospital of Linyi City, Yishui, Shandong, China.
出版信息
Expert Rev Clin Pharmacol. 2022 Jul;15(7):799-803. doi: 10.1080/17512433.2022.2103537. Epub 2022 Jul 24.
INTRODUCTION
Diabetic patients are prone to hypoglycemia when treated with insulin. Dasiglucagon is a water-soluble and ready-to-use glucagon analog developed for treating hypoglycemia in patients with diabetes.
AREAS COVERED
A comprehensive literature search was conducted in PubMed. Key search terms included dasiglucagon and hypoglycemia. The pharmacological characteristics, clinical evidence, and place in therapy of dasiglucagon were reviewed.
EXPERT OPINION
Dasiglucagon is a glucagon analog that is stable in water-soluble formulation. It can increase plasma glucose in a dose-dependent manner. Clinical studies have shown that dasiglucagon rapidly and effectively improved insulin-induced hypoglycemia in patients with diabetes. Dasiglucagon was well tolerated and the common adverse events included nausea and vomiting.
简介
接受胰岛素治疗的糖尿病患者容易发生低血糖。达格列净是一种水溶性、即用型胰高血糖素类似物，开发用于治疗糖尿病患者的低血糖。
涵盖领域
在 PubMed 上进行了全面的文献检索。主要搜索词包括达格列净和低血糖。综述了达格列净的药理学特征、临床证据和治疗地位。
专家意见
达格列净是一种稳定的水溶性制剂的胰高血糖素类似物。它可以剂量依赖性地增加血浆葡萄糖。临床研究表明，达格列净可迅速有效地改善糖尿病患者的胰岛素诱导性低血糖。达格列净具有良好的耐受性，常见的不良反应包括恶心和呕吐。
Zotero 插件